Skip to main content

Table 2 Metabolic risk factors in patients treated with Irbesartan with or without the metabolic syndrome

From: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

   Patients without the metabolic syndrome1 Patients with the metabolic syndrome1
Components of the Met. Syn. Baseline 3 months 9 months Reduction † Baseline 3 months 9 months Reduction †
Blood pressure mean ± SD mean ± SD mean ± SD   mean ± SD mean ± SD mean ± SD  
systolic mmHg 159.4 ± 13.3 136.8* ± 11.3 131.9* ± 10.0 -27.5 160.7 ± 13.4 139.1* ± 11.5 133.9* ± 10.5 -26.8
diastolic mmHg 93.7 ± 8.5 82.6* ± 7.5 79.9* ± 6.7 -13.8 94.3 ± 8.8 83.8* ± 7.6 80.8* ± 6.8 -13.5
Fasting plasma                
glucose mg/dL 91.5 ± 13.6 91.8 ± 13.5 92.6** ± 15.0 1.1 120.9 ± 30.1 114.2* ± 26.3 111.9* ± 25.0 -9.0
Abdominal obesity                
men cm 96.6 ± 10.2 96.1* ± 10.2 95.9* ± 10.1 -0.7 111.3 ± 12.8 109.9* ± 12.4 108.6* ± 12.6 -2.7
women cm 85.9 ± 11.9 85.5* ± 11.7 85.8** ± 11.8 -0.1 100.7 ± 14.6 100* ± 14.6 99.2* ± 14.3 -1.5
Triglycerides mg/dL 153.3 ± 42.2 151.9* ± 40.2 151.7* ± 41.1 -1.6 217.5 ± 62.5 196.6* ± 56.2 186.7* ± 53.2 -30.8
HDL cholesterol                
men mg/dL 48.6 ± 6.2 49.2* ± 6.1 49.4* ± 6.2 0.8 41.8 ± 7.6 44.2* ± 7.1 45.6* ± 7.0 3.8
women mg/dL 52.2 ± 5.6 52.2 ± 5.8 51.9 ± 5.8 -0.3 44.4 ± 7.4 46.6* ± 6.9 47.7* ± 6.7 3.3
  1. 1 doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baseline